Retinitis Pigmentosa Market Report 2026

Retinitis Pigmentosa Market Overview

• Retinitis Pigmentosa market size has reached to $12.15 billion in 2025 • Expected to grow to $18.31 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Rising Healthcare Expenditure Drives Growth In The Retinitis Pigmentosa Market • Market Trend: Innovative Gene Therapy Developments In Retinitis Pigmentosa • North America was the largest region in 2025.

What Is Covered Under Retinitis Pigmentosa Market?

Retinitis pigmentosa (RP) is a group of inherited disorders causing progressive degeneration of the retina, leading to vision loss. It primarily affects photoreceptor cells (rods and cones), resulting in symptoms such as night blindness and tunnel vision. Over time, RP can lead to significant visual impairment and blindness. The main types of retinitis pigmentosa are autosomal recessive, autosomal dominant, and x-linked. Autosomal recessive retinitis pigmentosa (AR-RP) is a form of disease where a person must inherit two copies of the mutated gene, one from each parent, to be affected. The treatment of retinitis pigmentosa includes vitamin A, docosahexaenoic acid (DHA), calcium channel blockers, gene therapy, retinal eye prosthetics, and others, and is diagnosed by electroretinogram, visual field testing, genetic testing, and others. The distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, and they are used by various end-users such as hospitals, specialty clinics, home care, and others.

What Is The Retinitis Pigmentosa Market Growth Forecast?

The retinitis pigmentosa market size is expected to see strong growth in the next few years. It will grow to $18.31 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing investments in gene therapy pipelines, rising demand for disease-modifying treatments, expansion of personalized medicine approaches, growing integration of assistive vision technologies, increasing focus on early genetic diagnosis. Major trends in the forecast period include increasing focus on gene-based therapies, rising adoption of retinal prosthetic devices, growing use of genetic testing for diagnosis, expansion of supportive vision enhancement solutions, enhanced research into disease-modifying treatments.

Global Retinitis Pigmentosa Market Segmentation

1) By Type: Autosomal Recessive, Autosomal Dominant, X-Linked 2) By Treatment: Vitamin A, Docosahexaenoic Acid (DHA), Calcium Channel Blockers, Gene Therapy, Retinal Eye Prosthetics, Other Treatments 3) By Diagnosis: Electroretinogram, Visual Field Testing, Genetic Testing, Other Diagnosis 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels 5) By End-users: Hospitals, Specialty Clinics, Homecare, Other End-users Subsegments: 1) By Autosomal Recessive: Early-Onset Autosomal Recessive Retinitis Pigmentosa, Late-Onset Autosomal Recessive Retinitis Pigmentosa 2) By Autosomal Dominant: Early-Onset Autosomal Dominant Retinitis Pigmentosa, Late-Onset Autosomal Dominant Retinitis Pigmentosa 3) By X-Linked: X-Linked Recessive Retinitis Pigmentosa, X-Linked Dominant Retinitis Pigmentosa

What Is The Driver Of The Retinitis Pigmentosa Market?

The increase in healthcare expenditure is expected to propel the growth of the retinitis pigmentosa market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare goods and services, including medical treatments, medications, hospitalizations, and preventive care, within a specified period, reflecting the overall cost of healthcare provision within a population. Healthcare expenditure is rising due to the increasing cost of advanced medical technologies, aging populations, and the prevalence of chronic diseases. Healthcare expenditure for retinitis pigmentosa is focused on advancing diagnostic methods, developing effective treatments, and providing supportive care to manage vision loss. For instance, in April 2025, according to the American Medical Association (AMA), a US-based professional association, U.S. health spending surged by 7.5% in 2023 to reach $4.9 trillion, averaging roughly $14,570 per person, a notable jump from the 4.6% growth rate seen in 2022. Therefore, the increase in healthcare expenditure is driving the growth of the retinitis pigmentosa industry.

Key Players In The Global Retinitis Pigmentosa Market

Major companies operating in the retinitis pigmentosa market are Johnson And Johnson, Novartis AG, AbbVie Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd, Spark Therapeutics, REGENXBIO Inc., Editas Medicine, IVERIC bio, MeiraGTx Holdings, Gensight Biologics, Second Sight Medical Products, Copernicus Therapeutics Inc., Kiora Pharmaceuticals, 4D Molecular Therapeutics, Acucela Inc., AGTC Applied Genetic Technologies Corporation, ProQR Therapeutics NV, Nanoscope Therapeutics Inc, Beacon Therapeutics Ltd, Horama SA, ViGeneron GmbH

Global Retinitis Pigmentosa Market Trends and Insights

Major companies operating in the retinitis pigmentosa market are increasingly focusing on developing innovative treatment options, such as gene therapy, to provide more effective and targeted solutions for managing and potentially curing this debilitating condition. Gene therapy for retinitis pigmentosa (RP) involves the delivery of functional genes to replace or repair the defective ones causing the disease. This innovative treatment aims to restore normal function to the affected photoreceptor cells in the retina, thereby slowing or potentially halting the progression of vision loss. For instance, in April 2024, ViGeneron GmbH, a Germany-based biotechnology company, launched a Phase Ib clinical trial to evaluate the safety, tolerability, and efficacy of VG901, a gene therapy designed to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The trial is an open-label, single-arm, dose-escalation study that will investigate the intravitreal injection of VG901 in patients with autosomal recessive RP due to biallelic CNGA1 mutations.

What Are Latest Mergers And Acquisitions In The Retinitis Pigmentosa Market?

In December 2023, Thea Pharma Inc., a France-based pharmaceutical company, acquired two antisense oligonucleotide (AON) treatments, Sepofarsen (LCA10) and Ultevursen (USH2A), from ProQR Therapeutics NV for an undisclosed amount. This acquisition supports Thea's focus on rare genetic eye diseases and ophthalmology. ProQR Therapeutics NV is a Netherlands-based biotechnology company that focuses on developing treatments for retinitis pigmentosa.

Regional Outlook

North America was the largest region in the retinitis pigmentosa market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Retinitis Pigmentosa Market?

The retinitis pigmentosa market consists of revenues earned by entities by providing services such as genetic counseling, low vision therapy, psychological support, and educational support. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinitis pigmentosa market also includes sales of retinal implants, screen readers, telescopic glasses, and adaptive lighting. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Retinitis Pigmentosa Market Report 2026?

The retinitis pigmentosa market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the retinitis pigmentosa industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.